Sanofi's (SNY) Genzyme announces the publication of results from its studies of Lemtrada in...

|About: Sanofi (SNY)|By:, SA News Editor

Sanofi's (SNY) Genzyme announces the publication of results from its studies of Lemtrada in patients with relapsing-remitting multiple sclerosis, in the November 1 online issue of The Lancet. Results show the drug was significantly more effective at reducing annualized relapse rates than its active competitor Rebif, and more patients on Lemtrada were relapse-free at two years. In addition, accumulation of disability was significantly slowed, and patients experienced actual improvement in disability scores, suggesting a reversal of disability in some patients. Shares +0.7% AH.